Oncolytic viruses as anticancer agents: clinical progress and remaining challenges.

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Immunotherapy has revolutionized cancer treatment but faces challenges with patient response and resistance.
• Oncolytic viruses are engineered to selectively destroy cancer cells and modulate the tumor microenvironment.
• Advances in cancer immunology and viral engineering have increased interest in oncolytic virus therapy.

Purpose of the Study:

• To review key milestones in the clinical development of oncolytic viruses.
• To discuss persistent challenges hindering widespread clinical implementation.
• To propose streamlined future research directions for patient benefit.

Main Methods:

• Review of clinical development milestones for oncolytic viruses.
• Analysis of current challenges in oncolytic virus therapy translation.
• Clinical reflection to inform future research strategies.

Main Results:

• Oncolytic viruses demonstrate potential in selectively targeting cancer cells and enhancing anti-tumor immunity.
• Despite promising preclinical and early clinical data, significant barriers impede widespread adoption.
• Key milestones in development have been achieved, but clinical translation lags.

Conclusions:

• Oncolytic virus therapy holds significant promise for cancer treatment by leveraging viral replication and immune stimulation.
• Addressing challenges in clinical translation, manufacturing, and delivery is crucial for success.
• Streamlining research and development efforts can accelerate the path to meaningful patient benefit.